Interestingly, while TP53 mutations were found in 9% (17/187) of the total AML samples, they were significantly enriched in tumors containing 11q23-25 amplification (5/10, 50%), as compared to tumors lacking 11q23-25 amplification (12/177, 6.8%) (p < 0.001) (Figures 4D and S8). Here, TP53 is linked to acute myeloid leukemia.